Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Breast Cancer

  Free Subscription


1 Ann Surg
4 Ann Surg Oncol
5 BMC Cancer
1 Br J Cancer
2 Breast Cancer Res
10 Breast Cancer Res Treat
4 Breast J
2 Cancer Cell
1 Cancer Epidemiol Biomarkers Prev
1 Cancer Res
1 Carcinogenesis
2 Clin Breast Cancer
1 Clin Cancer Res
1 Eur J Cancer
2 Eur J Surg Oncol
4 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Biol Chem
1 J Clin Oncol
1 J Nucl Med
2 J Surg Oncol
1 Lancet
1 Oncogene
1 Oncol Rep
2 PLoS Comput Biol
5 PLoS One
2 Proc Natl Acad Sci U S A
1 Radiology
1 Radiother Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Surg

  1. THOMPSON CK, Lee MK, Baker JL, Attai DJ, et al
    Taking a Second Look at Neoadjuvant Endocrine Therapy for the Treatment of Early Stage Estrogen Receptor Positive Breast Cancer During the COVID-19 Outbreak.
    Ann Surg. 2020;272:e96-e97.

    Ann Surg Oncol

  2. KRELL RW, Spanheimer PM
    Primary Site Surgery and Survival Impact in Metastatic HER2-Amplified Breast Cancer: Responsible use of Cohort Data.
    Ann Surg Oncol. 2020 Jul 22. pii: 10.1245/s10434-020-08868.

  3. ROSENKRANZ KM, Ballman K, McCall L, McCarthy C, et al
    Cosmetic Outcomes Following Breast-Conservation Surgery and Radiation for Multiple Ipsilateral Breast Cancer: Data from the Alliance Z11102 Study.
    Ann Surg Oncol. 2020 Jul 22. pii: 10.1245/s10434-020-08893.
    PubMed         Abstract available

    ASO Author Reflections: Is Breast Cancer Dissemination Lymphatic, Hematogenous, or Both; and Does It Matter?
    Ann Surg Oncol. 2020 Jul 21. pii: 10.1245/s10434-020-08932.

  5. LAWS A, Mulvey TM, Jalbert N, Dalton S, et al
    Baseline Screening MRI Uptake and Findings in Women with >/= 20% Lifetime Risk of Breast Cancer.
    Ann Surg Oncol. 2020 Jul 18. pii: 10.1245/s10434-020-08853.
    PubMed         Abstract available

    BMC Cancer

  6. HONG J, Huang J, Shen L, Zhu S, et al
    A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.
    BMC Cancer. 2020;20:663.
    PubMed         Abstract available

  7. BELLAT V, Verchere A, Ashe SA, Law B, et al
    Transcriptomic insight into salinomycin mechanisms in breast cancer cell lines: synergistic effects with dasatinib and induction of estrogen receptor beta.
    BMC Cancer. 2020;20:661.
    PubMed         Abstract available

  8. REY-VARGAS L, Mejia-Henao JC, Sanabria-Salas MC, Serrano-Gomez SJ, et al
    Effect of neoadjuvant therapy on breast cancer biomarker profile.
    BMC Cancer. 2020;20:675.
    PubMed         Abstract available

  9. SOLEIMANI DODARAN M, Borgoni S, Sofyali E, Verschure PJ, et al
    Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
    BMC Cancer. 2020;20:676.
    PubMed         Abstract available

  10. MCWILLIAMS L, Woof VG, Donnelly LS, Howell A, et al
    Risk stratified breast cancer screening: UK healthcare policy decision-making stakeholders' views on a low-risk breast screening pathway.
    BMC Cancer. 2020;20:680.
    PubMed         Abstract available

    Br J Cancer

  11. SIMON J, Chaix M, Billa O, Kamga AM, et al
    Survival in patients with HR+/HER2- metastatic breast cancer treated with initial endocrine therapy versus initial chemotherapy. A French population-based study.
    Br J Cancer. 2020 Jul 17. pii: 10.1038/s41416-020-0979.
    PubMed         Abstract available

    Breast Cancer Res

  12. MADIGAN LI, Dinh P, Graham JD
    Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
    Breast Cancer Res. 2020;22:77.
    PubMed         Abstract available

  13. MCGEE EE, Kim CH, Wang M, Spiegelman D, et al
    Erythrocyte membrane fatty acids and breast cancer risk by tumor tissue expression of immuno-inflammatory markers and fatty acid synthase: a nested case-control study.
    Breast Cancer Res. 2020;22:78.
    PubMed         Abstract available

    Breast Cancer Res Treat

  14. BORTNIK S, Tessier-Cloutier B, Leung S, Xu J, et al
    Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer.
    Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05795.
    PubMed         Abstract available

  15. DUDEK AZ, Liu LC, Fischer JH, Wiley EL, et al
    Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy.
    Breast Cancer Res Treat. 2020 Jul 22. pii: 10.1007/s10549-020-05787.
    PubMed         Abstract available

  16. KARLSSON F, Granath F, Smedby KE, Zedenius J, et al
    Sarcoma of the breast: breast cancer history as etiologic and prognostic factor-A population-based case-control study.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05802.
    PubMed         Abstract available

  17. CHEPIKOVA OE, Malin D, Strekalova E, Lukasheva EV, et al
    Lysine oxidase exposes a dependency on the thioredoxin antioxidant pathway in triple-negative breast cancer cells.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05801.
    PubMed         Abstract available

  18. YAP NY, Tan NYT, Tan CJ, Loh KW, et al
    Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05807.
    PubMed         Abstract available

  19. FASANO J, Shao T, Huang HH, Kessler AJ, et al
    Optimism and coping: do they influence health outcomes in women with breast cancer? A systemic review and meta-analysis.
    Breast Cancer Res Treat. 2020 Jul 21. pii: 10.1007/s10549-020-05800.
    PubMed         Abstract available

  20. MINAMI CA, King TA, Mittendorf EA
    Patient preferences for locoregional therapy in early-stage breast cancer.
    Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05737.
    PubMed         Abstract available

  21. SCHAIRER C, Laurent CA, Moy LM, Gierach GL, et al
    Obesity and related conditions and risk of inflammatory breast cancer: a nested case-control study.
    Breast Cancer Res Treat. 2020 Jul 20. pii: 10.1007/s10549-020-05785.
    PubMed         Abstract available

  22. FINN RS, Boer K, Bondarenko I, Patel R, et al
    Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
    Breast Cancer Res Treat. 2020 Jul 18. pii: 10.1007/s10549-020-05755.
    PubMed         Abstract available

  23. ARABANDI P, Slade AN, Sutton AL, McGuire KP, et al
    Racial differences in the relationship between surgical choice and subsequent patient-reported satisfaction outcomes among women with early-stage hormone-positive breast cancer.
    Breast Cancer Res Treat. 2020 Jul 16. pii: 10.1007/s10549-020-05784.
    PubMed         Abstract available

    Breast J

  24. DAMODARAN S, Sember QC, Arun BK
    Clinical implications of breast cancer tumor genomic testing.
    Breast J. 2020 Jul 22. doi: 10.1111/tbj.13966.
    PubMed         Abstract available

  25. SHAH PD, Domchek SM
    The contemporary landscape of genetic testing and breast cancer: Emerging issues.
    Breast J. 2020 Jul 20. doi: 10.1111/tbj.13968.
    PubMed         Abstract available

  26. CUFFOLO G, Gahir-Atwal HK, Smith B
    One-step nucleic acid amplification CK19 copy number for sentinel node biopsy in breast cancer: Identification of new cutoffs to predict nonsentinel axillary node involvement.
    Breast J. 2020 Jul 17. doi: 10.1111/tbj.13977.
    PubMed         Abstract available

  27. MAGNO S, Linardos M, Carnevale S, Dilucca M, et al
    The impact of the COVID-19 pandemic on breast cancer patients awaiting surgery: Observational survey in an Italian University hospital.
    Breast J. 2020 Jul 17. doi: 10.1111/tbj.13889.

    Cancer Cell

  28. SIERSBAEK R, Scabia V, Nagarajan S, Chernukhin I, et al
    IL6/STAT3 Signaling Hijacks Estrogen Receptor alpha Enhancers to Drive Breast Cancer Metastasis.
    Cancer Cell. 2020 Jul 6. pii: S1535-6108(20)30311.
    PubMed         Abstract available

  29. SUDHAN DR, Guerrero-Zotano A, Won H, Gonzalez Ericsson P, et al
    Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers.
    Cancer Cell. 2020;37:183-199.
    PubMed         Abstract available

    Cancer Epidemiol Biomarkers Prev

  30. REDING KW, Han CJ, Whittington D, Zahid M, et al
    Risk of breast cancer associated with estrogen DNA adduct biomarker.
    Cancer Epidemiol Biomarkers Prev. 2020 Jul 22. pii: 1055-9965.EPI-20-0133.
    PubMed         Abstract available

    Cancer Res

  31. WANG Y, Chen Y, Bao L, Zhang B, et al
    CHD4 promotes breast cancer progression as a coactivator of hypoxia-inducible factors.
    Cancer Res. 2020 Jul 22. pii: 0008-5472.CAN-20-1049.
    PubMed         Abstract available


  32. SHEN J, Song R, Chow WH, Zhao H, et al
    Homologous recombination repair capacity in peripheral blood lymphocytes and breast cancer risk.
    Carcinogenesis. 2020 Jul 21. pii: 5874561. doi: 10.1093.
    PubMed         Abstract available

    Clin Breast Cancer

  33. QAZVINI MG, Salehi Z, Mashayekhi F, Saedi HS, et al
    A33512C and Intronic Poly(AT) Insertion/Deletion (PAT-/+) Polymorphisms of the XPC Gene and Their Association With the Risk of Breast Cancer.
    Clin Breast Cancer. 2020 Jun 19. pii: S1526-8209(20)30142.
    PubMed         Abstract available

  34. MCCLELLAND S 3RD, Burney HN, Zellars RC, Ohri N, et al
    Predictors of Whole Breast Radiation Therapy Completion in Early Stage Breast Cancer Following Lumpectomy.
    Clin Breast Cancer. 2020 Jun 27. pii: S1526-8209(20)30150.
    PubMed         Abstract available

    Clin Cancer Res

  35. TOLANEY SM, Sahebjam S, Le Rhun E, Bachelot T, et al
    A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1764.
    PubMed         Abstract available

    Eur J Cancer

  36. SAMUEL E, Chiang C, Jennens R, Faulkner D, et al
    Response to letter commenting on: Fulvestrant falsely elevates oestradiol levels in immunoassays in postmenopausal women with breast cancer.
    Eur J Cancer. 2020 Jul 14. pii: S0959-8049(20)30339.

    Eur J Surg Oncol

  37. PEARCE BCS, Fiddes RN, Paramanathan N, Chand N, et al
    Extreme oncoplastic conservation is a safe new alternative to mastectomy.
    Eur J Surg Oncol. 2020;46:71-76.
    PubMed         Abstract available

  38. GUO R, Li L, Su Y, Xiu B, et al
    Current practice and barriers of mesh-assisted implant-based breast reconstruction in China: A nationwide cross-sectional survey of 110 hospitals.
    Eur J Surg Oncol. 2020;46:65-70.
    PubMed         Abstract available

    Int J Cancer

  39. YI ZB, Yu P, Zhang S, Wang WN, et al
    Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33227.
    PubMed         Abstract available

  40. ZIELONKE N, Kregting LM, Heijnsdijk EAM, Veerus P, et al
    The potential of breast cancer screening in Europe.
    Int J Cancer. 2020 Jul 19. doi: 10.1002/ijc.33204.
    PubMed         Abstract available

  41. JABAGI MJ, Vey N, Goncalves A, Le Tri T, et al
    Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: a nationwide population-based cohort.
    Int J Cancer. 2020 Jul 19. doi: 10.1002/ijc.33216.
    PubMed         Abstract available

  42. BARENHOLZ-COHEN T, Merkher Y, Haj J, Shechter D, et al
    Lung mechanics modifications facilitating metastasis are mediated in part by breast cancer derived extracellular vesicles.
    Int J Cancer. 2020 Jul 23. doi: 10.1002/ijc.33229.
    PubMed         Abstract available

    Int J Radiat Oncol Biol Phys

  43. SHAH C, Smith BD, Royce TJ
    Balancing Treatment Deintensification Strategies in Early Stage Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2020;107:959-963.

    J Biol Chem

  44. ZHANG P, Yang Y, Qian K, Li L, et al
    A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing HER2 expression in breast cancer.
    J Biol Chem. 2020 Jul 20. pii: RA119.010759. doi: 10.1074/jbc.RA119.010759.
    PubMed         Abstract available

    J Clin Oncol

  45. SAURA C, Oliveira M, Feng YH, Dai MS, et al
    Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >/= 2 HER2-Directed Regimens: Phase III NALA Trial.
    J Clin Oncol. 2020 Jul 17:JCO2000147. doi: 10.1200/JCO.20.00147.
    PubMed         Abstract available

    J Nucl Med

  46. ULANER GA, Jhaveri K, Chardarlapaty S, Hatzoglou V, et al
    Head-to-head evaluation of (18)F-FES and (18)F-FDG PET/CT in metastatic invasive lobular breast cancer.
    J Nucl Med. 2020 Jul 17. pii: jnumed.120.247882. doi: 10.2967/jnumed.120.247882.
    PubMed         Abstract available

    J Surg Oncol

  47. BRUNELLE CL, Roberts SA, Shui AM, Gillespie TC, et al
    Reply to: Bergmann et al comment to "Patients who report cording after breast cancer surgery are at higher risk of lymphedema: Results from a large prospective screening cohort".
    J Surg Oncol. 2020 Jul 22. doi: 10.1002/jso.26132.

  48. BERGMANN A, Baiocchi JMT, de Andrade MFC, Thuler LCS, et al
    Comment to "Patients who report cording after breast cancer surgery are at higher risk of lymphedema: Results from a large prospective screening cohort".
    J Surg Oncol. 2020 Jul 22. doi: 10.1002/jso.26094.


  49. SHIEH Y, Tice JA
    Medications for Primary Prevention of Breast Cancer.
    JAMA. 2020;324:291-292.

  50. GRAHAM D, DiNome ML, Ganz PA
    Breast Cancer Risk-Reducing Medications.
    JAMA. 2020;324:310.


  51. GINSBURG O, Horton R
    A Lancet Commission on women and cancer.
    Lancet. 2020;396:11-13.


  52. BUSCHHAUS JM, Humphries BA, Eckley SS, Robison TH, et al
    Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow.
    Oncogene. 2020 Jul 16. pii: 10.1038/s41388-020-01391.
    PubMed         Abstract available

    Oncol Rep

  53. LI W, Sang M, Hao X, Wu Y, et al
    CTLA4 blockade combined with 5aza2'deoxycytidine enhances the killing effect of MAGEA family common antigen peptidespecific cytotoxic T cells on breast cancer.
    Oncol Rep. 2020 Jul 21. doi: 10.3892/or.2020.7701.
    PubMed         Abstract available

    PLoS Comput Biol

  54. YANG KD, Damodaran K, Venkatachalapathy S, Soylemezoglu AC, et al
    Predicting cell lineages using autoencoders and optimal transport.
    PLoS Comput Biol. 2020;16:e1007828.
    PubMed         Abstract available

  55. VSEVOLOZHSKAYA OA, Shi M, Hu F, Zaykin DV, et al
    DOT: Gene-set analysis by combining decorrelated association statistics.
    PLoS Comput Biol. 2020;16:e1007819.
    PubMed         Abstract available

    PLoS One

  56. WALSH CA, Akrap N, Garre E, Magnusson Y, et al
    The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer.
    PLoS One. 2020;15:e0236187.
    PubMed         Abstract available

  57. SHAHZAD N, Munir T, Javed M, Tasneem F, et al
    SHISA3, an antagonist of the Wnt/beta-catenin signaling, is epigenetically silenced and its ectopic expression suppresses growth in breast cancer.
    PLoS One. 2020;15:e0236192.
    PubMed         Abstract available

  58. AKIN E, Pelen NN, Tiryaki IU, Yalcin F, et al
    Parameter identification for gompertz and logistic dynamic equations.
    PLoS One. 2020;15:e0230582.
    PubMed         Abstract available

  59. GASILINA A, Premnauth G, Gurjar P, Biesiada J, et al
    IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models.
    PLoS One. 2020;15:e0229801.
    PubMed         Abstract available

  60. BARE DJ, Cherny VV, DeCoursey TE, Abukhdeir AM, et al
    Expression and function of voltage gated proton channels (Hv1) in MDA-MB-231 cells.
    PLoS One. 2020;15:e0227522.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  61. CARVAJAL-GARCIA J, Cho JE, Carvajal-Garcia P, Feng W, et al
    Mechanistic basis for microhomology identification and genome scarring by polymerase theta.
    Proc Natl Acad Sci U S A. 2020;117:8476-8485.
    PubMed         Abstract available

  62. KUMAR S, Singh SK, Viswakarma N, Sondarva G, et al
    Mixed lineage kinase 3 inhibition induces T cell activation and cytotoxicity.
    Proc Natl Acad Sci U S A. 2020;117:7961-7970.
    PubMed         Abstract available


  63. PINKER K
    Preoperative MRI Improves Surgical Planning and Outcomes for Ductal Carcinoma in Situ.
    Radiology. 2020 Mar 17:200076. doi: 10.1148/radiol.2020200076.

    Radiother Oncol

  64. JOURNY N, Schonfeld SJ, Hauptmann M, Roberti S, et al
    Dose-volume effects of breast cancer radiation therapy on the risk of second oesophageal cancer.
    Radiother Oncol. 2020 Jul 14. pii: S0167-8140(20)30415.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.